B
16.38
-0.45 (-2.67%)
| Previous Close | 16.83 |
| Open | 16.97 |
| Volume | 256,046 |
| Avg. Volume (3M) | 699,720 |
| Market Cap | 897,328,320 |
| Price / Earnings (TTM) | 3.04 |
| Price / Book | 2.44 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Diluted EPS (TTM) | -1.69 |
| Total Debt/Equity (MRQ) | 0.13% |
| Current Ratio (MRQ) | 24.62 |
| Operating Cash Flow (TTM) | -88.27 M |
| Levered Free Cash Flow (TTM) | -53.72 M |
| Return on Assets (TTM) | -13.84% |
| Return on Equity (TTM) | -27.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Bicara Therapeutics Inc. | Bullish | Bearish |
AIStockmoo Score
-0.3
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.25 |
|
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 11.65% |
| % Held by Institutions | 89.28% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (Wedbush, 83.15%) | Buy |
| Median | 23.00 (40.42%) | |
| Low | 11.00 (Wells Fargo, -32.85%) | Hold |
| Average | 21.75 (32.78%) | |
| Total | 2 Buy, 2 Hold | |
| Avg. Price @ Call | 16.72 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 13 Jan 2026 | 30.00 (83.15%) | Buy | 17.95 |
| BTIG | 08 Jan 2026 | 28.00 (70.94%) | Buy | 16.56 |
| Mizuho | 18 Dec 2025 | 18.00 (9.89%) | Hold | 17.64 |
| Wells Fargo | 11 Nov 2025 | 11.00 (-32.84%) | Hold | 14.73 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |